Innate Pharma SA (NAS:IPHA)
$ 1.8413 -0.0034 (-0.18%) Market Cap: 149.05 Mil Enterprise Value: 88.69 Mil PE Ratio: 0 PB Ratio: 4.52 GF Score: 58/100

Q1 2023 Innate Pharma SA Earnings Call Transcript

May 10, 2023 / 12:00PM GMT
Release Date Price: $2.94 (-3.77%)
Operator

Thank you for joining the Innate Pharma Publication of Revenue for First Quarter 2023 Conference Call. (Operator Instructions) Finally, I would like to remind all participants that this call is being recorded.

Without further ado, I am pleased to introduce Henry Wheeler, Vice President, Investor Relations and Communications. Henry, over to you.

Henry Wheeler
Innate Pharma S.A. - VP of IR & Communication

Thank you. Good morning, good afternoon, and welcome, everyone. This morning, Innate issued a press release providing a business update for Q1 2023. We look forward to highlighting the progress made during the year to-date as well as addressing future goals and milestones. The press release and today's presentation are both available on the IR section of our website.

On Slide 2, before we start, I'd like to remind you that we will make forward-looking statements regarding the financial outlook in addition to regulatory and product plan development. These statements are subject to risks and uncertainties that may cause actual results to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot